Source: International Congress 2018 – Scientific Year in Review



Rating:

Share or cite this content

Citations should be made in the following way:
L. Segal (New York New York, NY, United States of America). The microbiome, cancer development and response to therapy. International Congress 2018 – Scientific Year in Review

Member's Comments

No comment yet.

Related content which might interest you: Role of biomarkers for early detection of lung cancer and chemoprevention Source: Eur Respir J 2002; 19: 1151-1158 Year: 2002 The role of radiation therapy in the management of small cell lung cancer Source: Breathe, 13 (4) e87; 10.1183/20734735.009617 Year: 2017 The biology of lung cancer Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=61 Year: 2001 Impact of antibiotics on immunotherapy response in lung cancer patients Source: International Congress 2019 – Treatment of lung cancer Year: 2019 How to evaluate the immune status of lung cancer patients before immunotherapy Source: Breathe, 13 (4) 291; 10.1183/20734735.001917 Year: 2017 From ineffective tumor immune response to immunomodulation in lung cancer Source: ERS Research Seminar 2017 – Immunotherapy: a new standard of care in thoracic malignancies? Year: 2017 Effect of autoimmune diseases on risk and survival in histology-specific lung cancer Source: Eur Respir J 2012; 40: 1489-1495 Year: 2012 The terms of adaptation of functional systems of patients with lung cancer and secondary inflammatory changes after surgical treatment Source: Eur Respir J 2006; 28: Suppl. 50, 750s Year: 2006 Emerging concern of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017 The role of molecular pathology in diagnosis and treatment of lung cancer Source: Annual Congress 2007 - PG9 - Molecular pathology and genetics in lung diseases Year: 2007 A possible role of intracellular calcium in the development of anti-cancer therapy -resistance in lung cancer cells Source: Eur Respir J 2006; 28: Suppl. 50, 853s Year: 2006 Lung cancer: does age affect treatment strategy? Source: Eur Respir Mon; 2009: 43:306–326 Year: 2009 How to define the immune status of lung cancer patient Source: International Congress 2015 – Stop immune tolerance in lung cancer! Year: 2015 Advances in target therapy in lung cancer Source: Eur Respir Rev 2015; 24: 23-29 Year: 2015 Advances in target therapy for lung cancer Source: International Congress 2014 – Ceremony for the ERS Romain Pauwels Research Award 2014 - Clinical Year in Review I Year: 2014 Systemic therapy. non small cell lung cancer stage I and II: treatment standards and new development Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Treatment of extensive-stage small cell lung carcinoma: current status and future prospects Source: Eur Respir J 2010; 35: 202-215 Year: 2010 New and emerging targeted treatments in advanced lung cancer Source: International Congress 2016 – Lung cancer: latest developments in screening and patient management Year: 2016